期刊
NATURE BIOMEDICAL ENGINEERING
卷 4, 期 7, 页码 732-742出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41551-020-0573-2
关键词
-
资金
- National Key R&D Program of China [2018YFA0208900, 2018YFE0205300]
- Strategic Priority Research Program of Chinese Academy of Sciences [XDB36000000]
- National Natural Science Foundation of China [31730032, 31820103004, 31728007, 81871489, 91859118]
- K.C. Wong Education Foundation [GJTD-2018-03]
- National Postdoctoral Program for Innovative Talents [BX20180083]
The combination of tumour-infarction therapy and chemotherapy, delivered via nanoparticles decorated with a tumour-homing peptide and encapsulating thrombin and doxorubicin, outperforms the corresponding monotherapies in tumour-bearing mice and rabbits. Drugs that induce thrombosis in the tumour vasculature have not resulted in long-term tumour eradication owing to tumour regrowth from tissue in the surviving rim of the tumour, where tumour cells can derive nutrients from adjacent non-tumoral blood vessels and tissues. Here, we report the performance of a combination of tumour-infarction therapy and chemotherapy, delivered via chitosan-based nanoparticles decorated with a tumour-homing peptide targeting fibrin-fibronectin complexes overexpressed on tumour-vessel walls and in tumour stroma, and encapsulating the coagulation-inducing protease thrombin and the chemotherapeutic doxorubicin. Systemic administration of the nanoparticles into mice and rabbits bearing subcutaneous or orthotopic tumours resulted in higher tumour growth suppression and decreased tumour recurrence than nanoparticles delivering only thrombin or doxorubicin, with histological and haematological analyses indicating an absence of detectable toxicity. The co-administration of a cytotoxic payload and a protease to elicit vascular infarction in tumours with biodegradable tumour-targeted nanoparticles represents a promising strategy for improving the therapeutic index of coagulation-based tumour therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据